Default

Allergy and immunology

Anaesthesia

Basic research

Cardiovascular medicine

Complementary medicine and alternative therapies

Critical care / intensive care

Dentistry / oral medicine

Dermatology

Emergency medicine

Endocrinology

Epidemiology

Ethics

Evidence-based medicine

Gastroenterology

Genetics

Geriatric medicine / aging

Haematology / blood transfusion

Health economics

Health policy

History of medicine

Infectious diseases

Internal medicine

Laboratory medicine

Medical education

Medical informatics

Neurology

Nursing

Nutrition and metabolism

Obstetrics and gynaecology

Occupational and environmental medicine

Oncology

Ophthalmology

Organisation of health care

Otolaryngology / head and neck surgery

Paediatrics

Palliative care

Pathology

Patient-physician relationship

Pharmacology and therapeutics

Primary care, family medicine

Psychiatry and psychotherapy

Psychosomatics

Public health

Quality of care

Radiology

Rehabilitation medicine

Renal medicine

Respiratory medicine

Rheumatology

Sexual medicine

Sports medicine

Statistics and research methods

Surgery

Transplantation

Travel medicine

Urology

Ops! No article found. Reset filter

37-year incidence and mortality time trends of common cancer types by sex, age, and stage in the canton of Zurich

Original article
Wanner M, Matthes KL, Karavasiloglou N, Limam M, Korol D, Rohrmann S
Swiss Med Wkly. 2020;150:w20388

The Cancer Registry Zurich, Zug, Schaffhausen and Schwyz is one of the oldest cancer registries in Switzerland, first registering tumours in 1980 for the canton of Zurich. The aim of this study was to analyse trends in incidence and mortality for the most common types of cancer in the canton of Zurich from 1981 to 2017.

Expert recommendation from the Swiss Amyloidosis Network (SAN) for systemic AL-amyloidosis

Review article: Medical guidelines
Schwotzer R, Flammer AJ, Gerull S, Pabst T, Arosio P, Averaimo M, Bacher VU, Bode P, Cavalli A, Concoluci A, Dirnhofer S, Djerbi N, Dobner SW, Fehr T, Garofalo M, Gaspert A, Heimgartner R, Hübers A, Jung HH, Kessler C, Knöpfel R, Laptseva N, Manka R, Mazzucchelli L, Meyer M, Mihaylova V, Monney P, Mylonas A, Nkoulou R, Pazhenkottil A, Pfister O, Rüfer A, Schmidt A, Seeger H, Stämpfli SF, Stirnimann G, Suter T, Théaudin M, Treglia G, Tzankov A, Vetter F, Zweier M, Gerber B
Swiss Med Wkly. 2020;150:w20364

These are the Swiss Amyloidosis Network recommendations which focus on diagnostic work-up and treatment of AL-amyloidosis. One aim of this meeting was to establish a consensus guideline regarding the diagnostic work-up and the treatment recommendations for systemic amyloidosis tailored to the Swiss health care system.

Fluoropyrimidine chemotherapy: recommendations for DPYD genotyping and therapeutic drug monitoring of the Swiss Group of Pharmacogenomics and Personalised Therapy

Review article: Medical guidelines
Hamzic S, Aebi S, Joerger M, Montemurro M, Ansari M, Amstutz U, Largiadèr C
Swiss Med Wkly. 2020;150:w20375

The authors discuss current guidelines on genotype-guided fluoropyrimidine dosing and therapeutic drug monitoring, and propose recommendations tailored to the situation in Switzerland to facilitate their clinical uptake for the further individualisation of fluoropyrimidine chemotherapy.

Immune checkpoint inhibitor therapy-associated encephalitis: a case series and review of the literature

Original article
Stuby J, Herren T, Schwegler Naumburger G, Papet C, Rudiger A
Swiss Med Wkly. 2020;150:w20377

Encephalitis should be suspected in patients treated with immune checkpoint inhibitors who present with rapidly evolving confusion. Blood tests, CSF analysis, cerebral MRI and an EEG should be performed. Therapy with intravenous corticosteroids is recommended. Steroid unresponsiveness is rare and should lead to a review of the diagnosis. Alternative treatment options are IVIG, plasma exchange therapy and rituximab.

Supplementum 247: Swiss Hematology & Oncology Congress (SOHC)

Supplement
Swiss Med Wkly. 2020;150:w20411

Healthcare professionals’ opinions on psychological screening in follow-up care for childhood cancer survivors

Original article
Harju E, Hendriks MJ, Roser K, Michel G
Swiss Med Wkly. 2020;150:w20356

There is overall agreement that screening for psychological late effects is not yet standard in follow-up care in Switzerland. It is important to mitigate perceived barriers and concerns of healthcare professionals to enable a successful implementation of psychological distress screening according to the established standards of care.

Concordance of tumour characteristics and survival clustering among pairs of first-degree relatives with breast cancer

Original article
Rapiti E, Tille JC, Fournier E, Saiji E, Weintraub D, Bouzourene H, Viassolo V, Bouchardy C, Chappuis PO, Benhamou S
Swiss Med Wkly. 2020;150:w20327

Family history is a known risk factor for breast cancer, but its prognostic value and the prognostic value of tumour characteristics in relation to family history has not been clearly established.

Management of hepatocellular carcinoma: SASL expert opinion statement

Review article: Medical guidelines
Goossens N, Toso C, Heim MH
Swiss Med Wkly. 2020;150:w20296

This expert opinion statement by the Swiss Association for the Study of the Liver reviews the current state of HCC management and provides recommendations adapted to the health care environment in Switzerland.

Swiss newborn screening for severe T and B cell deficiency with a combined TREC/KREC assay – management recommendations

Review article: Biomedical intelligence
Trück J, Prader S, Natalucci G, Hagmann C, Brotschi B, Kelly J, Bassler D, Steindl K, Rauch A, Baumgartner M, Fingerhut R, Hauri-Hohl M, Güngör T, Pachlopnik Schmid J, Berger C, Reichenbach J
Swiss Med Wkly. 2020;150:w20254

The recent introduction of newborn screening for severe primary T and B cell deficiencies in Switzerland allows rapid identification of patients with severe combined immunodeficiency (SCID). The authors outline the screening procedure currently performed in Switzerland and give recommendations for diagnostic evaluations and precautionary measures against infection in children with abnormal screening test results.

Swiss experience of atezolizumab for platinum-pretreated urinary tract carcinoma: the SAUL study in real-world practice

Original article
Cathomas R, Schardt J, Pless M, Llado A, Mach N, Riklin C, Haefeli J, Fear S, Stenner F
Swiss Med Wkly. 2020;150:w20223

Atezolizumab is an approved therapy for urothelial carcinoma based on results from phase II and III trials. The global SAUL study evaluated atezolizumab in a broader patient population more representative of real-world populations.

Verpassen Sie keinen Artikel!

close